Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Bicara Therapeutics Stock

Q: How to sell Bicara Therapeutics stock?

If you hold private company shares of Bicara Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Bicara Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

www.bicara.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $355.03MM

Bicara Therapeutics, founded in 2020, is a clinical-stage company striving to develop biologics for cancer patient treatments. Bicara uses tumor-targeting antibodies and the tumor-microenvironment aiming to impact the tumor site for a hardwearing effect. Working to advance cancer treatment for patients who have had difficulty with first- and second-line therapies, Bicara partners with chemistry, manufacturing, and controls (CMC) experts and professional protein engineers who have a history of progressing FDA-approved drugs. Bicara Therapeutics is headquartered in Cambridge, Massachusetts.

Buy or sell Bicara Therapeutics stockLearn more about Bicara Therapeutics IPO

OverviewFinancingsValuation

Enterprise Value

Access Bicara Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Bicara Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Bicara Therapeutics investors also invested in these private companies

Premji Invest

BillionToOne, Navan, Devoted Health, Hippocratic AI, MapBox, Apttus, Heyday, Enveda Biosciences, Lenskart, Bicara Therapeutics

Ra Capital Management

X-energy, Element Biosciences, Mindtickle, BioAge, Freenome, Capstan Therapeutics, Synthego, Sionna Therapeutics, FogPharma, Bicara Therapeutics

F-Prime Capital

Neo4j, Carrot, Devoted Health, Icertis, Owkin, Ashby, Hone, TraceLink, Engrail Therapeutics, GoodData

TPG

Tanium, Acorns, Calm, Varo, Kaseya, Kajabi, Palmetto, Ohmium, Monogram Health, Monolith Materials

Deerfield Management

Insilico Medicine, LetsGetChecked, FogPharma, Epic Sciences, Bicara Therapeutics, Lark Technologies, Frontier Medicines, Crossover Health, Intus Care, Twill

Janus Henderson Investors

Element Biosciences, Freenome, Parse Biosciences, Scorpion Therapeutics, Carmot Therapeutics, Bicara Therapeutics, Obsidian Therapeutics, Bigfoot Biomedical, Asher Biotherapeutics, Lycia Therapeutics

The Invus Group

Meow Wolf, Scorpion Therapeutics, FogPharma, Cardurion Pharma, Bicara Therapeutics, PayJoy, Hemab Therapeutics, Asher Biotherapeutics, Endeavor BioMedicines, Lycia Therapeutics

ImpactAssets

Rad AI, Trove, Devoted Health, Pachama, Xcimer Energy, Bicara Therapeutics, Phil's Finest

Aisling Capital

Braidwell

Fairmount Partners

Acorn Bioventures

Bioqube Ventures

Red Tree Venture Capital

Engrail Therapeutics, Bicara Therapeutics

Vedanta Capital

Bicara Therapeutics

Biocon

Bicara Therapeutics

Omega Funds

Alumis, Scorpion Therapeutics, Bicara Therapeutics, Endeavor BioMedicines

Team

Management Team

Claire Mazumdar Ph.D

Chief Executive Officer

Ryan Cohlhepp Ph.D

Chief Operating Officer & President

Ivan Hyep

Chief Financial Officer

David Raben MD

Chief Medical Officer

Board Members

Carolyn Ng Ph.D

TPG

Heath Lukatch Ph.D

Red Tree Venture Capital

Jake Simson Ph.D

RA Capital Management

Ketan Patel MD

F-Prime Capital

Kiran Mazumdar-Shaw

Biocon

Bicara Therapeutics stock FAQs

Can you buy Bicara Therapeutics stock?

As Bicara Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Bicara Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Bicara Therapeutics stock?

To invest in a private company like Bicara Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Bicara Therapeutics stock?

Yes, you may be able to sell your Bicara Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Bicara Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Bicara Therapeutics stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Bicara Therapeutics a public company?

No, Bicara Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Bicara Therapeutics’ stock price?

Bicara Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Bicara Therapeutics’ private market stock price with Forge Data.

What is Bicara Therapeutics’ stock ticker symbol?

Bicara Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Fierce Biotech 12/12/2023

Bicara nets second nine-digit haul in nine months, raising $165M series C

Venture capitalists and biotech CEOs have been largely speaking with one voice this year with respect to the state of new financing, underscoring that the only thing that matters is having enough money to last until the next catalyst. Bicara Therapeutics is acting on that advice, closing a $165 million series C just nine months after raising a $108 million series B. The new round is quadruple the $40 million secured by Bicara when it launched in 2021.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Bicara Therapeutics Stock

Register To Buy and Sell Shares

Enterprise Value

Access Bicara Therapeutics’ valuation and stock price.

Bicara Therapeutics investors also invested in these private companies

Team

Management Team

Board Members

Bicara Therapeutics stock FAQs

Can you buy Bicara Therapeutics stock?

How to buy Bicara Therapeutics stock?

Can you sell Bicara Therapeutics stock?

How to sell Bicara Therapeutics stock?

Is Bicara Therapeutics a public company?

What is Bicara Therapeutics’ stock price?

What is Bicara Therapeutics’ stock ticker symbol?

Can institutional investors buy and sell private market stocks?

Other companies like Bicara Therapeutics in the BioTech & Pharma sector

Bicara nets second nine-digit haul in nine months, raising $165M series C

Frequently Asked Questions

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES